Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly announced that its next-generation weight loss drug, retatrutide, successfully passed a late-stage trial for obesity treatment. The drug demonstrated significant weight loss results, with some patients losing over 28% of their body weight. This development positions Lilly to seek approval for retatrutide, which could become a key player in the competitive weight loss drug market.
- ▪Retatrutide helped patients lose an average of 28.3% of their weight over 80 weeks.
- ▪Approximately 45% of participants in the trial achieved 30% or more weight loss.
- ▪The drug is expected to generate significant sales, potentially reaching $3.8 billion by 2030.
6 outlets in our directory ran this story, first to last over 8 hours. Coverage spans 3 points on the political spectrum — 1 lean left, 3 centre, 1 right.
- ▪ New obesity drug from Lilly delivers major weight loss — The Hill
- ▪ New Eli Lilly weight loss drug has dramatic effects in clinical trial — Washington Examiner
- ▪ A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says — TIME — Top
- ▪ Eli Lilly's next-generation weight loss injection posted record results in obesity trial — Quartz
- ▪ New Weight Loss Drug Retatrutide Delivers Stunning Results — TODAY.com
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | US Top News and Analysis |
| Canonical URL | https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html |
| Publication time | Thu, 21 May 2026 13:43:14 GMT |
| Retrieval time | 2026-05-21T10:51:10.728Z |
| Last seen | 2026-05-21T14:11:07.424Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | aBS1rBimYei- · 6 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly on Thursday said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing shots and pills from both Lilly and Novo Nordisk. It also appears to be more effective than those options.The highest dose of retatrutide helped patients lose 28.3% of their weight — or 70.3 pounds — on average over 80 weeks, compared to 2.2% with placebo, when evaluating only patients who stayed on the drug.Roughly 45% of the 2,500 patients in the Phase 3 trial achieved 30% or more weight loss, Lilly said.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at US Top News and Analysis.
Discussion
0 commentsMore from US Top News and Analysis
